THE ROLE OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) IN OVARIAN CANCER WITH PERITONEAL CARCINOMATOSIS IN STAGES III AND IV
Keywords:
Ovarian cancer, peritoneal carcinomatosis, vascular endothelial growth factor (VEGF), tumor angiogenesis, biomarker, prognosisAbstract
Ovarian cancer, particularly in advanced stages III and IV with peritoneal carcinomatosis (PC), presents significant challenges in treatment and prognosis. Vascular endothelial growth factor (VEGF) has been identified as a key regulator of tumor angiogenesis, facilitating tumor progression, metastasis, and resistance to therapy. This study aimed to evaluate the concentration of VEGF in plasma and peritoneal effusion in patients with ovarian cancer and to explore its prognostic significance. A total of 35 patients undergoing cytoreductive surgery were analyzed, and VEGF levels were assessed using enzyme-linked immunosorbent assay (ELISA). Additionally, high VEGF expression was found to be associated with poor prognosis, reduced progression-free survival, and overall survival in stage IV patients. These findings underscore the importance of VEGF as a potential prognostic biomarker and therapeutic target in ovarian cancer with peritoneal carcinomatosis. Further research is warranted to explore targeted anti-VEGF strategies to improve patient outcomes.
References
Ferrara N. VEGF: an update on biological and therapeutic aspects. Nature Medicine. 2019;25(6):946-958.
Folkman J. Tumor angiogenesis: therapeutic implications. The New England Journal of Medicine. 1971;285(21):1182-1186.
Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407(6801):249-257.
Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. The New England Journal of Medicine. 2011;365(26):2473-2483.
OH Ubaydullayevna, EB Sobirovna, SN Yusupovna //The optimization of early diagnosis of cervical cancer and its recurrences - Conferencea, 2023
OH Ubaydullayevna, EB Sobirovna, MM Bakhtiyorovich//Prediction and study of the occurrence of cervical cancer recurrence International Journal of Medical Sciences And Clinical Research 3 (04), 121-124
Esankulova Bustonoy Sobirovna, Ulmasov Firdavs Gayratovich//Analysis of the tumor microenvironment of ovarian tumors using immunohistochemistry// Биология ва тиббиёт муаммолари 2024, №5 (156)
Alimjanovich , R. Z., Maxammatkulovich , R. N., & Khikmatovich , K. K. (2022). Age Features of the Prevalence of Prostate Cancer in Uzbekistan. Central Asian Journal of Medical and Natural Science, 3(5), 154-157. Retrieved from
Rizaev Jasur , Rakhimov Nodir , Kodyrov Khamidullo , Shakhanova Shakhnoza . Study of prostate cancer death by regions of the republic of Uzbekistan.Journal of Biomedicine and Practice. 2022, vol . 7, issue 5, pp.202-210
Nodir RM, Shaxnoza SS, Farhod R. Development of new approaches in the treatment of metastatic renal cell carcinoma //Journal of research in health science. – 2020. – T. 5. – no. 4. – pp. 82-95.
ShSh Shakhanova , NM Rakhimov. Multimodal approach to the treatment of multiple osteogenic metastases of kidney and prostate cancer . Clinical and Experimental Oncology 2020, No. 4 Page 50-56.
Ulmasov F.G., Esankulova B.S. Immunohistochemical study of the ovarian cancer microenvironment at different stages: the role of immune cells in tumor progression // Journal of Biomedicine and Practice. 2024, vol. 9, issue 5, pp.
